Trial Profile
A Phase 1, Single-Dose, Double-Blind, Placebo-and Active-Controlled, Randomized, 6-way Crossover Human Abuse Liability Evaluation of ALKS 5461
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2018
Price :
$35
*
At a glance
- Drugs Buprenorphine/samidorphan (Primary) ; Buprenorphine
- Indications Cocaine-related disorders
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Alkermes plc
- 13 Aug 2018 Results published in the Journal of Clinical Pharmacology
- 09 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Apr 2015 New trial record